文献速递造血干细胞移植与细胞治疗

如何治疗CAR T细胞治疗后难治性CRS和ICANS

How I treat refractory CRS and ICANS after CAR T-cell therapy.
PubMed 文献 · Blood · 2023-01-01

本文以病例讨论形式,聚焦CAR T细胞治疗后对一线干预(托珠单抗或糖皮质激素)难治的细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS),讨论其管理方法、严重毒性危险因素、阿那白滞素的新兴应用及支持治疗措施。

要点

  • 建立CRS和ICANS的共识诊断标准及托珠单抗与糖皮质激素的稳定使用对CAR T细胞疗法推广至关重要。
  • 预防性干预可减少严重毒性,使体弱及高危患者也能接受CAR T细胞治疗。
  • 持续或进展性CRS和ICANS仍损害患者结局且治疗困难,本文讨论其管理策略。

核心结论

  • 对一线托珠单抗或糖皮质激素治疗后持续或进展的难治性CRS和ICANS,本文讨论了其管理方法、危险因素、阿那白滞素的新兴应用及支持治疗措施。

研究设计与样本

  • 本文为病例讨论,聚焦对一线干预难治的CRS和/或ICANS系列病例。

主要发现

  • 预防性干预可减少严重毒性,使体弱及高危患者也能接受CAR T细胞治疗。
  • 持续或进展性CRS和ICANS仍损害患者结局且治疗具有挑战性。
  • 本文讨论了阿那白滞素的新兴应用及改善难治性毒性患者结局的缓解策略和支持治疗措施。

临床怎么用

  • 本文讨论了在初始托珠单抗或糖皮质激素给药后持续或进展的难治性毒性的管理方法。
  • 本文强调了阿那白滞素的新兴应用及改善难治性毒性患者结局的支持治疗措施。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly because of the expanding indications for standard-of-care treatment and the development of new investigational products. The establishment of consensus diagnostic criteria for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), alongside the steady use of both tocilizumab and corticosteroids for treatment, have been essential in facilitating the widespread use. Preemptive interventions to prevent more severe toxicities have improved safety, facilitating CAR T-cell therapy in medically frail populations and in those at high risk of severe CRS/ICANS. Nonetheless, the development of persistent or progressive CRS and ICANS remains problematic because it impairs patient outcomes and is challenging to treat. In this case-based discussion, we highlight a series of cases of CRS and/or ICANS refractory to front-line interventions. We discuss our approach to managing refractory toxicities that persist or progress beyond initial tocilizumab or corticosteroid administration, delineate risk factors for severe toxicities, highlight the emerging use of anakinra, and review mitigation strategies and supportive care measures to improve outcomes in patients who develop these refractory toxicities.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jain MD, Smith M, Shah NN, et al. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023. PMID: 36989488. doi:10.1182/blood.2022017414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。